

# Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19

Chaja F. Jacobs,<sup>1-4</sup> Eric Eldering,<sup>1,3-5</sup> and Arnon P. Kater<sup>2-5</sup>

<sup>1</sup>Department of Experimental Immunology and <sup>2</sup>Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands;

<sup>3</sup>Cancer Center Amsterdam, Amsterdam, The Netherlands; <sup>4</sup>Amsterdam Institute for Infection & Immunity, Amsterdam, The Netherlands; and <sup>5</sup>Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands

Tyrosine kinase inhibitors (TKIs) are used to target dysregulated signaling pathways in virtually all hematologic malignancies. Many of the targeted signaling pathways are also essential in nonmalignant immune cells. The current coronavirus severe acute respiratory syndrome coronavirus 2 pandemic catalyzed clinical exploration of TKIs in the treatment of the various stages of COVID-19, which are characterized by distinct immune-related complications. Most of the reported effects of TKIs on immune regulation have been explored *in vitro*, with different class-specific drugs having nonoverlapping target affinities. Moreover, many of the reported *in vivo* effects are based on artificial animal models or on observations made in symptomatic patients with a hematologic malignancy who often already suffer from disturbed immune regulation. Based on *in vitro* and clinical observations, we attempt to decipher the impact of the main TKIs approved or in late-stage development for the treatment of hematological malignancies, including inhibitors of Bruton's tyrosine kinase, spleen tyrosine kinase, BCR-Abl, phosphatidylinositol 3-kinase/mammalian target of rapamycin, JAK/STAT, and FMS-like tyrosine kinase 3, to provide a rationale for how such inhibitors could modify clinical courses of diseases, such as COVID-19.

## Introduction

Over the last decades, dysregulation of signaling pathways involved in proliferation, activation, and survival have been identified in virtually all hematologic malignancies. This has led to the development and application of a diverse set of tyrosine kinase inhibitors (TKIs) that have drastically improved the clinical outcomes of these diseases.<sup>1</sup>

In addition to their role in tumorigenesis, many of the targeted signaling pathways are essential in nonmalignant immune cells. Furthermore, many TKIs have significant off-target effects.<sup>1</sup>

Their immunomodulatory effects led to an increased interest in TKIs developed for hematologic malignancies in applications other than cancer. The current coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic catalyzed clinical exploration of TKIs in the treatment of the various stages of COVID-19.<sup>2</sup> Because a standard treatment for COVID-19 is still lacking, drug repurposing strategies for TKIs are being considered in the management of this potentially lethal disease. Despite the vast number of publications on TKIs, an up-to-date systematic review on the presently exploited immunomodulatory effects of TKIs is lacking. We focus on the main TKIs approved or in late-stage development for the treatment of hematological malignancies: Bruton's tyrosine kinase (BTK), spleen tyrosine kinase (SYK), BCR-Abl, phosphatidylinositol 3-kinase (PI3K)/mammalian target of

Submitted 6 November 2020; accepted 28 December 2020; published online 9 February 2021. DOI 10.1182/bloodadvances.2020003768.

Send data sharing request via email to the corresponding author, Arnon P. Kater, a.p.kater@amsterdamumc.nl.

The full-text version of this article contains a data supplement.

© 2021 by The American Society of Hematology

**Table 1. TKIs, their indications, and the (off-target) kinases they inhibit**

Class/drugs	Indication (T)rial/(R)egistration/(O)ff-label	Relevant immunomodulatory off-target molecules
<b>BTK*</b>		
Ibrutinib	CLL/SLL(R), WM(R), MCL(R), MZL(R), BCL(R), cGvHD(R) <sup>103</sup>	ITK, EGFR, JAK3 <sup>103</sup>
Acalabrutinib	CLL/SLL(R), NHL(R), MCL(R) <sup>104</sup>	
Zanubrutinib	MZL(R), CLL/SLL(T), WM(T), MCL(T) <sup>105</sup>	
Tirabrutinib	CLL(T), BCL(T), WM(T), PCNSL(T) <sup>104</sup>	
<b>SYK†</b>		
Fostamatinib	ITP(R), RA(T), CLL(T), BCL(T) <sup>106,107</sup>	FLT3, JAK2 <sup>63,108</sup>
Entospletinib	AML(T), CLL(T), BCL(T), GvHD(T), MCL(T), NHL(T) <sup>106</sup>	JAK2 <sup>106</sup>
Cerdulatinib	DLBCL(T), CLL(T), NHL(T) <sup>106</sup>	JAK1/JAK3, AKT, NF-κB <sup>106,107</sup>
<b>BCR-Abi‡</b>		
Imatinib	Ph <sup>+</sup> CML(R) <sup>109</sup>	
Nilotinib	Ph <sup>+</sup> CML(R) <sup>110</sup>	
Dasatinib	Ph <sup>+</sup> CML(R) <sup>58</sup>	BTK <sup>58</sup>
Bosutinib	Ph <sup>+</sup> CML(R), Ph <sup>+</sup> ALL(R) <sup>111</sup>	
Ponatinib	Ph <sup>+</sup> CML(R), Ph <sup>+</sup> ALL(R) <sup>111</sup>	Abl, FLT3 <sup>111</sup>
Radotinib	Ph <sup>+</sup> CML(R) <sup>112</sup>	
<b>PI3K/mTOR§</b>		
Idelalisib (p110δ)	ALL(R), CLL/SLL(R), FL(R) <sup>113</sup>	
Copanlisib (PI3Kδ & PI3Kε)	FL(R), CLL/SLL(R) <sup>114,115</sup>	
Duvelisib	FL(R), CLL/SLL(R) <sup>115</sup>	
Umbralisib (PI3Kδ)	MZL(T), CLL(T), FL(T), DLBCL(T) <sup>116</sup>	
Temsirolimus	NHL(R), MCL(R) <sup>117</sup>	
<b>JAK¶</b>		
Ruxolitinib (JAK1/2)	PV(R), MF(R), GvHD(R) <sup>118</sup>	
Fedratinib (JAK2)	MF(R) <sup>119</sup>	FLT3, BCR-Abi <sup>120</sup>
Momelotinib (JAK1/2)	MPN(T) <sup>121</sup>	
Pacritinib (JAK2)	MPN(T) <sup>122</sup>	FLT3 <sup>122</sup>
<b>FLT3  </b>		
Midostaurin	FLT3-mutated AML(R), ASM(R), MC(R) <sup>123</sup>	SYK <sup>123</sup>
Sunitinib	RCC(R), GI(R), FLT3-mutated AML(O) <sup>124</sup>	
Sorafenib	HCC(R), RCC(R), FLT3-mutated AML(O) <sup>125</sup>	
Gilteritinib	FLT3-mutated AML(R) <sup>125</sup>	
Crenolanib	FLT3-mutated AML(T) <sup>125</sup>	
Quizartinib	FLT3-mutated AML(T) <sup>125</sup>	

AKT, protein kinase B; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; ASM, aggressive systemic mastocytosis; BCL, B-cell lymphoma; cGvHD, chronic graft-versus-host disease; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; DLBCL, diffuse large B-cell lymphoma; EGFR, epidermal growth factor receptor; FL, follicular non-Hodgkin lymphoma; GI, gastrointestinal tumors; GvHD, graft-versus-host disease; HCC, hepatocellular carcinoma; ITP, idiopathic thrombocytopenic purpura; ITK, interleukin-2-inducible T-cell kinase; MC, mast cell leukemia; MCL, mantle cell lymphoma; MF, myelofibrosis; MPN, myeloproliferative neoplasm; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; PCNSL, primary central nervous system lymphoma; Ph<sup>+</sup>, Philadelphia chromosome positive; PV, polycythemia vera; RA, rheumatoid arthritis; RCC, renal cell carcinoma; SLL, small lymphocytic leukemia; WM, Waldenström macroglobulinemia.

\*Summarized in supplemental Table 1.

†Summarized in supplemental Table 2.

‡Summarized in supplemental Table 3.

§Summarized in supplemental Table 4.

¶Summarized in supplemental Table 5.

||Summarized in supplemental Table 6.

rapamycin (mTOR), JAK/STAT, and FMS-like tyrosine kinase 3 (FLT3). First, we summarize the putative roles of these kinases in innate (neutrophils, dendritic cells [DCs], monocytes, and natural killer [NK] cells) and adaptive (B cells and T cells) immune cells and then systematically discuss in vitro and in vivo evidence for their

effects in these cells to provide a rationale for how such inhibitors could modify clinical courses of diseases, such as COVID-19. COVID-19 has major global impacts on health and economy, and our understanding of its underlying pathophysiological mechanisms has progressed with unprecedented speed. The pandemic has also

triggered a storm of studies on treatment options and vaccine development. Amid this ongoing research, any review has the obvious limitation that current knowledge may quickly be outdated. Nevertheless, current and future research on COVID-19 and other diseases characterized by immune-related complications could benefit from an overview of the immunomodulatory effects of TKIs provided in this review.

## The main TKIs and their targets

TKIs, their indications, and the clinically relevant (off-target) kinases that they inhibit, will be discussed and summarized in Table 1. The available data on their immunomodulatory effects are summarized by TKI class in supplemental Tables 1 through 6.

## Role of the target kinases BTK, SYK, BCR-Abl, PI3K/mTOR, JAK/STAT, and FLT3 in normal immune function


### The innate immune system

Cells of the innate immune system act as first responders for the detection and clearance of (viral) infections.<sup>3</sup> They secrete proinflammatory cytokines that inhibit viral replication, stimulate the adaptive immune response, and recruit other immune cells to

the site of infection.<sup>3</sup> A schematic overview of a normal immune response during a viral infection can be found in Figure 1.

Granulocytes and monocytes detect extracellular pathogens via Toll-like receptors (TLRs).<sup>4</sup> Granulocytes will release enzymes and toxic proteins at the site of infection, whereas monocytes traffic to inflamed tissues and differentiate into (cytokine-producing) macrophages and monocyte-derived DCs.<sup>3</sup> Macrophages and neutrophils phagocytose and destroy pathogens, as well as infected cells. These sequential processes within neutrophils and monocytes require complex signaling cascades that involve BTK, SYK, Abl, PI3K/mTOR, and JAK/STAT.<sup>3,5-8</sup> BTK is involved in granulocyte maturation, and SYK signaling is required for leukocyte adhesion, pathogen recognition, and phagocytosis.<sup>8-10</sup> Abl is critical in podosome formation and the function of macrophages and is required for neutrophil recruitment and migration.<sup>6,7</sup> PI3K/mTOR modulate oxidative bursts in neutrophils and limit TLR signaling in macrophages.<sup>11</sup> JAK/STAT is involved in cytokine production of macrophages, as well as in the differentiation, survival, and activation of neutrophils.<sup>8,12</sup>

Activated DCs present pathogen-derived antigens to naive helper T (Th) cells to initiate the adaptive immune response.<sup>3</sup> BTK mediates maturation and antigen presentation, whereas SYK is involved in the production of reactive oxygen species and recognition of tissue damage, and PI3K negatively regulates TLR signaling in DCs.<sup>5,10,11</sup>



**Figure 1. Schematic overview of the normal immune after a viral infection.** Phase 0 consists of epithelial infection with the virus, after which monocytes detect the pathogen and subsequent cytokine production and differentiate into cytokine-producing macrophages and other cell types. Phase 1 entails the attraction and activation of other innate immune cells, such as NK cells, which kill infected cells, and DCs, which then travel to naive T cells and lymph nodes. Phase 2 consists of the subsequent activation of T cells and B cells by DCs (and the cytokines produced) into activated and differentiated T cells and antibody-producing plasma cells, respectively. This results in phase 3, in which antibodies and T cells attack the virus and virus-infected cells, respectively. Image created with Biorender.com.

JAK/STAT signaling is involved in their maturation, antigen presentation, and cytokine production.<sup>11,12</sup>

NK cells kill infected cells via degranulation, receptor-mediated apoptosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). Their maturation and activation are mediated by BTK and PI3K/mTOR, whereas PI3K/mTOR and JAK/STAT are involved in cytokine production.<sup>11,13,14</sup> Their cytolytic function is supported by PI3K/mTOR and (indirectly) by FLT3.<sup>11,15</sup>

### The adaptive immune system

Responses of the adaptive immune system are based on antigen-specific receptors expressed on T- and B-cell surfaces. T-cell receptors recognize peptide fragments when presented by antigen-presenting cells, such as DCs.<sup>3</sup> The (cytotoxic) CD8<sup>+</sup> subset primarily kills infected cells, whereas the CD4<sup>+</sup> subset regulates cellular and humoral responses and contains the immunosuppressive regulatory T-cell (Treg) subset.<sup>3,11</sup> CD4<sup>+</sup> cells differentiate into Th1, Th2, and Th17 cells. Th1 cells lead to an increased cell-mediated response, and Th2 cells lead to a humoral immune response. Th17 cells are developmentally distinct from Th1 and Th2 lineages and specifically produce proinflammatory interleukin-17 (IL-17).<sup>3</sup> SYK and Abl are involved in early T-cell development and maturation, whereas PI3K signaling is involved in the proliferative responses of all T cells and the survival of Tregs.<sup>10,16</sup> JAK/STAT signaling plays a key role in T-cell responses, specifically with respect to differentiation and cytokine production.<sup>12</sup>

B cells express (and produce) different classes of immunoglobulins based on their maturation and activation status.<sup>3</sup> After activation by binding of antigen to the B-cell receptor, B cells undergo affinity-based differentiation into plasma cells that produce specific antibodies, or into memory cells that can rapidly respond following reencounter of their specific antigen.<sup>3</sup> BTK and PI3K/mTOR form fundamental parts of the B-cell receptor–signaling cascade in which SYK acts as upstream signal transducer. Activation of this cascade leads to key processes that are involved in proliferation, differentiation, and survival.<sup>10,17,18</sup> JAK/STAT signaling is involved in the process of class switching.

### Impact of the main TKIs on the immune response

Based on above-described roles of these kinases in innate and adaptive immunity, it may seem predictable how TKIs will affect immune responses. Be that as it may, effects of TKIs on immune regulation have primarily been explored in vitro with different class-specific drugs having nonoverlapping target affinities. Moreover, many of the reported in vivo effects are based on artificial animal models or observed in symptomatic patients with a hematologic malignancy who often already suffer from disturbed immune regulation. Furthermore, because TKIs have effects on innate and adaptive immune functions, the timing of administration within the infectious cycle and development could greatly influence the response. Effects of a specific inhibitor within a TKI class can also differ greatly, because these inhibitors display distinct drug-protein interactions and off-target kinase-inhibition profiles, also resulting in inconsistent immunomodulatory effects.<sup>19</sup> Bearing in mind these caveats, we attempt to delineate the impact of the major TKIs on the frequency and function of each cell type of the innate and the adaptive immune response.

### Innate immune cells

**Monocytes/neutrophils.** The SYK and JAK inhibitors, fostamatinib and ruxolitinib, respectively, are associated with acquired neutropenia, without neutrophil dysfunctions.<sup>20,21</sup> TKI-induced functional alterations of neutrophils and monocyte-derived cells have been widely reported. Duvelisib improves macrophage function by polarizing them to an M1 phenotype, in contrast to the immunosuppressive effects seen with other PI3K inhibitors.<sup>22</sup> Most BCR-Abl inhibitors improve monocyte chemotaxis.<sup>23</sup> mTOR inhibition by temsirolimus stimulates neutrophil and macrophages infiltration into lung epithelium, possibly explaining the interstitial lung disease seen in temsirolimus-treated patients.<sup>24</sup> Impairment of activation and cytotoxicity/phagocytosis of neutrophils and monocytes occur in patients treated with ibrutinib or idelalisib.<sup>25-27</sup> Proliferation and cytokine production is reduced by the SYK and JAK inhibitors fostamatinib, ruxolitinib and fedratinib.<sup>28-30</sup>

In summary, granulocyte and monocyte function is impaired by inhibitors of BTK, SYK, and JAK and improved by Abl and mTOR inhibitors. PI3K inhibitors seem to have stimulating and suppressive effects in distinct cell types.

**DCs.** DC maturation and activation are improved by ibrutinib in vitro.<sup>31</sup> However, SYK and JAK inhibition with fostamatinib and ruxolitinib, respectively, decreases signaling, activation, and differentiation.<sup>32,33</sup> Because ruxolitinib's effect on DCs is expected to be due to on-target JAK inhibition, it is expected that all JAK inhibitors impair DC function.<sup>32</sup> Midostaurin decreases DC differentiation and activation, and sorafenib limits their migration and T-cell activation, both seen in vitro.<sup>34,35</sup> Because sunitinib does not have any effects on the functionality of DCs, it remains questionable whether the aforementioned effects are the actual results of FLT3 inhibition.<sup>35</sup> Treatment with BCR-Abl inhibitors can result in suppression and improvement of DC expansion and function (including antitumor effects), depending on the timing and duration of drug exposure.<sup>36</sup> This might be explained by the negative impact on DC maturation and differentiation (eg, lower levels of costimulatory molecules) observed with long-term imatinib cultures of progenitor cells in vitro but the increased chemotaxis seen during short-term cultures of mature DCs.<sup>37,38</sup>

Thus, DC function is decreased by SYK, JAK, and FLT3 inhibition and increased by the BTK inhibitor ibrutinib, whereas the effects of BCR-Abl inhibitors depend on the timing and duration of drug exposure.

**NK cells.** Alterations in the frequency of NK cells occur during treatment with BCR-Abl and JAK inhibitors. An increased NK cell/lymphocyte ratio is observed in chronic myeloid leukemia (CML) patients treated with dasatinib, imatinib, and nilotinib.<sup>39</sup> Ruxolitinib treatment leads to an absolute decrease in NK cells in patients with myeloproliferative neoplasms, likely caused by an increased ratio of immature/mature subsets.<sup>40,41</sup> At the functional level, sorafenib increases degranulation and interferon- $\gamma$  (IFN- $\gamma$ ) secretion, possibly leading to more antitumor NK cell activity.<sup>42</sup> However, granule exocytosis and the cytotoxic function of NK cells are reduced in patients treated with ibrutinib, as well as in vitro by idelalisib.<sup>43-45</sup> Data on the suppression of NK cell activity by the more selective BTK inhibitors are conflicting, with less pronounced effects with acalabrutinib and zanubrutinib but equal suppression of ADCC with tirabrutinib and ibrutinib.<sup>45</sup> Whether BTK inhibitors potentiate or

**Table 2. Ongoing trials with TKIs in treatment of COVID-19**

Class/agent	Goal	Comments
<b>BTK</b>		
Ibrutinib	Efficacy in reducing respiratory failure	Quadruple-blind RCT, NCT04375397
	Efficacy in reducing respiratory failure and preventing death	Double-blind RCT, NCT04439006
Acalabrutinib	Efficacy in preventing deterioration, mortality, and respiratory failure or speeding up recovery of hospitalized patients with COVID-19	Multiarm RCT, 2020-001736-95 (ACCORD 2)
Zanubrutinib	Efficacy in increasing proportion of respiratory failure-free patients	Double-blind RCT, NCT04382586
<b>SYK</b>		
Fostamatinib	Efficacy in reducing mortality, SAEs, inflammatory biomarkers, and hospital admission	RCT, 2020-001750-22
	Efficacy in preventing progression to severe/critical disease	Double-blind RCT, NCT04629703
<b>BCR-Abi</b>		
Imatinib	Efficacy in preventing vascular leak	Single blind-RCT, 2020-001236-10
	Efficacy of baricitinib, imatinib, or lopinavir in combination with hydroxychloroquine	RCT, 2020-001321-31
	Efficacy in preventing need for invasive mechanical ventilation	RCT, NCT04422678
	Safety and efficacy in hospitalized adults	Double-blind RCT, NCT04394416
	Time to clinical improvement with treatment with hydroxychloroquine in combination with baricitinib, imatinib, or lopinavir/ritonavir	RCT, 2020-001321-31
	Time to clinical improvement	RCT, NCT04346147
	Efficacy in preventing severe COVID-19 in hospitalized aged patients	RCT, NCT04357613
<b>PI3K/mTOR</b>		
Duvelisib	Overall survival, length of hospital/ICU stay	Triple-blind RCT, NCT04372602
	Efficacy in requirement for mechanical ventilation or dying	Double-blind RCT, NCT04487886
Temsirrolimus	Efficacy in preventing respiratory failure	Double-blind RCT, NCT04482712
	Time to clinical recovery and viral clearance	Single-blind RCT, NCT04461340
	Proportion of patients alive and free from advanced respiratory support measures	Quadruple-blind RCT, NCT04341675
<b>JAK</b>		
Ruxolitinib	Efficacy in reducing mortality, SAEs, inflammatory biomarkers, and hospital admission	RCT, 2020-001750-22
	Incidence of SAEs and severe disease, safety	Single arm, NCT04348071
	Efficacy in preventing clinical worsening of respiratory status	Single arm, NCT04414098
	Treatment of cytokine storm	Open label, NCT04355793
	Efficacy in preventing death and influencing SAEs/ICU-free days	Double-blind RCT, NCT04377620
	Recovery from pneumonia	Open label, NCT04334044
	Efficacy in reducing respiratory failure and ICU care and preventing death	Double-blind RCT, NCT04362137, NCT04337359
	Reduction of cytokine load by single plasma volume exchanges, with or without ruxolitinib	Open label, NCT04374149
	Efficacy in reversing hyperinflammation (CIS)	Open label, NCT04338958
	Efficacy in preventing death, ICU admission, or mechanical ventilation	Triple-blind RCT, NCT04477993
	Efficacy in preventing SAEs and COVID-19 patients from becoming critically ill	Single arm, NCT04331665
	Overall survival	Open label, NCT04359290
	Efficacy in preventing severe respiratory failure and reducing ICU/hospital stay and survival, in combination with simvastatin	Open label, NCT04348695
	Ability to prevent all-cause mortality, noninvasive or invasive ventilation	Double-blind RCT, NCT04581954
	Ability to achieve a change from baseline in the clinical assessment score COVID-19 with colchicine, ruxolitinib, secukinumab, or standard treatment	Open label, NCT04403243

CIS, chronic inflammation score; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; RCT, randomized controlled trial; SAE, serious adverse event.

Downloaded from <http://ashpublications.net/bloodadvances/article-pdf/5/3/913/1799483/advancesadv202003768.pdf> by guest on 07 May 2024

**Table 2. (continued)**

Class/agent	Goal	Comments
	Safety and efficacy of ruxolitinib combined with mesenchymal stem cells	Single-blind RCT, ChiCTR2000029580
	Efficacy and safety in patients on respiratory support or approaching need for respiratory support	Open label, 2020-001459-42
	Efficacy of anakinra/tocilizumab, alone or in combination with ruxolitinib, in increasing ventilation-free days	Open-label RCT, 2020-001754-21, NCT04424056
	Clinical and biological efficacy of anakinra, alone or in combination with ruxolitinib, in reducing oxygen dependency, need for invasive ventilation, and systemic inflammation	Open-label RCT, 2020-001963-10
	Efficacy in preventing deterioration requiring mechanical ventilation	Open label, 2020-001777-71
	Overall survival after 28 d	Single arm, 2020-001732-10
Pacritinib	Efficacy in preventing mechanical ventilation or ECMO	Double-blind RCT, NCT04404361

CIS, chronic inflammation score; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; RCT, randomized controlled trial; SAE, serious adverse event.

suppress anti-CD20–induced ADCC is still a matter of debate, as reviewed recently.<sup>46</sup> Because many of the necessary cytokines in NK cell development and maturation exert their impact through JAK/STAT signaling, blocking the effects of IL-2 and IL-15 by ruxolitinib, fedratinib, and momelotinib prevents (in different degrees) activation and therefore IFN- $\gamma$  and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) secretion of NK cells in vitro, hampering their killing capacity.<sup>40,41,45</sup> NK cell–related effects of BCR-Abl inhibitors are not uniform. Although nilotinib suppresses NK cell reactivity in CML patients, dasatinib treatment results in enhanced reactivity through an unknown mechanism.<sup>23</sup>

In summary, NK cell cytotoxicity is impaired by BTK inhibitors, to the greatest extent by ibrutinib. PI3K and JAK/STAT inhibition lower the killing capacity and cytokine production, whereas BCR-Abl inhibition has variable effects. On the other hand, FLT3 inhibition increases NK cell function.

### Adaptive immune cells

**T cells.** T cells (subsets) are frequently altered during TKI treatment. Ibrutinib increases total CD4<sup>+</sup> and CD8<sup>+</sup> T cells in chronic lymphocytic leukemia (CLL) patients without lymphocytosis; however, in patients with significant tumor burden, ibrutinib decreases total T-cell numbers, which could be viewed as pseudonormalization.<sup>47</sup> Ibrutinib and (the more selective) zanubrutinib increase the frequency of Th17 cells and reduce the number of Tregs in CLL patients, possibly resulting in a more immune-supportive phenotype.<sup>47,48</sup> Treg frequency is also reduced by idelalisib, which correlates with autoimmune-related toxicities, as reviewed by Greenwell et al.<sup>49</sup> Tregs are probably less affected by umbralisib, because it leads to less severe T-cell–mediated toxicity than seen with idelalisib.<sup>50</sup> Imatinib, ruxolitinib, and certain FLT3 inhibitors also reduce Treg numbers.<sup>35,39,51-53</sup>

Functional T-cell alterations occur with most TKIs, although they vary in effect and degree. Ibrutinib reverses the polarization of CD4<sup>+</sup> Th2 cells to a Th1 cell phenotype through off-target ITK inhibition.<sup>54</sup> Ibrutinib, as well as the more selective BTK inhibitors, reduces the (over)activated T-cell state of CLL patients, as measured by lower plasma cytokine levels and decreased exhaustion.<sup>47,55,56</sup> These observations are probably the indirect result of on-target (BTK) effects on leukemia cells, resulting in

decreased suppressive interactions of the malignant B cells with T cells.<sup>57</sup> Sorafenib and sunitinib treatment also results in lower PD-1 expression on CD4<sup>+</sup> and CD8<sup>+</sup> T cells in vivo and in vitro, respectively.<sup>53,58</sup>


Low-dose sorafenib also increases activation, whereas high-dose sorafenib decreases T-cell proliferation and augments PD-1 expression.<sup>59</sup> Furthermore, low-dose sorafenib increases tumor-infiltrating T cells compared with high-dose sorafenib treatment of hepatocellular carcinoma patients in vivo, consistent with the dose-dependent immunomodulatory effects seen in vitro.<sup>58,59</sup> The increased T-effector activation observed during idelalisib and duvelisib treatment is caused, at least in part, by Treg inhibition.<sup>49</sup> Furthermore, mTOR inhibition by temsirolimus increases differentiation and enhances the function of Tregs.<sup>60</sup> Sunitinib and sorafenib improve the Th1-type response in vivo, most likely through off-target effects.<sup>58,61,62</sup>

On the other hand, fostamatinib, entospletinib, and cerdulatinib reduce activation, proliferation, and cytokine production of T cells in vitro.<sup>63</sup> All JAK inhibitors lower T-cell proliferation and cytokine secretion, resulting in less proinflammatory signals.<sup>64</sup> Th1 cytokine production is inhibited by midostaurin in vitro.<sup>65</sup>

BCR-Abl inhibitors again produce various effects; although nilotinib reduces T-cell activation in vivo, dasatinib treatment leads to enhanced proliferation of T cells in leukemia patients, which correlates with improved disease responses.<sup>39,58</sup> The effects of imatinib on T cells are conflicting, as reviewed in detail.<sup>38,66</sup>

Altogether, BTK inhibitors lead to changes in absolute T-cell numbers (depending on the clinical status of the patient) and skewing of specific subsets within the T-cell population. They also lead to reduced T-cell exhaustion. BTK, BCR-Abl, PI3K, JAK, and FLT3 inhibitors lower Treg numbers. SYK and PI3K inhibition reduces T-cell function, whereas mTOR inhibition promotes it. Effects of BCR-Abl inhibition are inconsistent between available drugs. JAK/STAT inhibition results in diminished T-cell function over multiple aspects. The effect of FLT3 inhibitors is dose dependent, with low doses leading to improved T-cell functions.

**B cells.** Because many TKIs are targeted toward hematological malignancies occurring in B cells, they also have various effects on



**Figure 2. Hypothetical application of TKIs during the SARS-CoV-2-induced immunopathology.** Phase 0 consists of infection with the virus; phase 1 entails the polarization of macrophages to an M1 phenotype (and their subsequent activation) and their production of cytokines to attract other immune cells. Phase 2 is the recruitment and activation of cytokine-producing innate immune cells and T cells and B cells, which (together with the cytokine storm that results from phase 1) results in phase 3: depletion and exhaustion of lymphocytes and, subsequently, secondary bacterial infections. In phase 4, acute respiratory distress syndrome, secondary infections and multi-organ failure arise, leading to respiratory insufficiency and life-threatening situations. The applicable TKIs are indicated below the phases during which their immunomodulatory effects would be the most beneficial. Image created with Biorender.com.

healthy B cells. These are significantly less sensitive to ibrutinib-, momelotinib-, or idelalisib-induced apoptosis than their malignant counterparts, resulting in stable B-cell numbers.<sup>45,55</sup> However, B-cell numbers and immunoglobulin levels decrease in CML patients treated with any of the BCR-Abl inhibitors, without changes in B-cell subsets.<sup>67</sup> Although fostamatinib clearly reduces the number of class-switched germinal center B cells, contradictory results have been reported with regard to fostamatinib's effect on the total B-cell number.<sup>28,33</sup>

In terms of functional changes, decreased immunoglobulin G (IgG) levels are observed in CLL patients after treatment with ibrutinib.<sup>55,68</sup> Likewise, IgM levels are decreased by ibrutinib in the graft-versus-host disease setting.<sup>69</sup> However, humoral immunity seems to be positively affected by ibrutinib. Increased IgA has been observed across clinical trials of ibrutinib, and patients with greater

improvements in IgA developed fewer infections.<sup>70</sup> Similarly, although IgM and IgG remain unaffected, acalabrutinib treatment also augments IgA levels.<sup>70</sup> CLL patients on ibrutinib also respond better to influenza vaccination than do untreated patients, but titers are diminished compared with healthy individuals.<sup>71</sup> Effects on B cells in CML patients differ among BCR-Abl inhibitors. Although imatinib reduces all immunoglobulin levels, dasatinib only lowers IgM, bosutinib only lowers IgG, and nilotinib does not incite any immunoglobulin decrease.<sup>36,67,72</sup>

Fostamatinib and cerdulatinib lower B-cell activation and BCR-mediated antigen presentation in vitro and attenuate autoantibody production by B cells in vivo, most likely through on-target SYK inhibition.<sup>33,73</sup> The effect of FLT3 inhibitors on B cells is modest, with only midostaurin showing an in vitro negative effect on the viability of B cells.<sup>74</sup> Although proliferation and IgG production in

healthy B cells are decreased by idelalisib *in vitro*, this is not seen upon idelalisib treatment *in vivo*.<sup>45</sup>

In summary, antibody changes are seen after BTK, BCR-Abl, and, possibly, PI3K inhibition. SYK inhibitors lower B-cell (auto)activity.

## Immunomodulation in relation to SARS-CoV-2

The high morbidity and mortality of the current COVID-19 pandemic and the lack of effective treatment has driven research toward application of TKIs outside of the malignant spectrum. Immune-related complications by SARS-CoV-2 infection and other inflammatory diseases led to the consideration of these inhibitors as treatment options. The initial “innate” phase of SARS-CoV-2 infection is set in motion following entry in nasal and bronchial epithelial cells through the viral structural spike protein binding to the angiotensin-converting enzyme 2 receptor.<sup>75</sup> Like most viral infections, tissue-resident macrophages in close proximity to infected cells will incite a proinflammatory state, resulting in recruitment of innate immune cells and cytokine production, leading to subsequent activation of adaptive immune responses.<sup>75</sup> However, in the case of (severe) COVID-19, massive invasion of innate immune cells into the infected tissues leads to hyperproduction of such cytokines, eventually resulting in a so-called “cytokine storm.”<sup>76</sup> As a consequence, recruited T cells reach a state of exhaustion, resulting in T-cell dysfunction and depletion that cause lymphopenia.<sup>76</sup> These detrimental inflammatory effects can potentially result in acute respiratory distress syndrome (ARDS), secondary infections, multiple organ failure, and death.<sup>76</sup> This chain of events might be interrupted by blocking specific kinases at different phases of the disease. Based on the data and considerations summarized above, we attempt to hypothetically assess the immunomodulatory potential of the TKIs in the pathophysiological process of COVID-19. Ongoing trials with these TKIs are summarized in Table 2. A schematic summary of the hypothetical application and timing of TKIs in COVID-19 is shown in Figure 2.

### BTK inhibitors

Ibrutinib reduces macrophage numbers, activation, infiltration, and degranulation.<sup>77,78</sup> Moreover, ibrutinib treatment decreases serum levels of inflammatory cytokines associated with cytokine release syndrome, such as IL-1 $\beta$ , IL-6, IL-10, and TNF- $\alpha$ .<sup>79</sup> In addition, ibrutinib polarizes the T-cell population toward effector cells and reduces their exhaustion marker expression, which possibly enables the adaptive immune system to a more capable immune response.<sup>56,80</sup> B-cell activation and a subsequent increase in IgG levels, which are both inhibited by ibrutinib, are specifically increased in patients with severe COVID-19.<sup>45,68,76</sup> Because of these immunomodulatory effects, ibrutinib, and perhaps the more selective BTK inhibitors as well, might be beneficial in the early and late stages of COVID-19.<sup>81</sup> However, zanubrutinib also lowers Tregs in CLL patients and could potentially ameliorate immune responses.<sup>48</sup> First results of a clinical trial with acalabrutinib in COVID-19 (the CALAVI trial) showed decreased IL-6 levels, reflecting the inhibition of monocytes and attenuation of their cytokine production.<sup>82</sup> However, it was recently reported that the trial did not meet its primary end point of increasing the patient proportion remaining alive and free of respiratory failure. It remains to be seen whether specific subgroups of patients benefit from acalabrutinib treatment.<sup>83</sup>

### SYK inhibitors

The SYK inhibitors affect some of the essential players in the cytokine storm seen in severe COVID-19 patients: IL-6, IL-10, and TNF- $\alpha$ .<sup>28,63,84</sup> Entospletinib also reduces pulmonary inflammation by macrophages and increases Treg numbers, which might mitigate the lung damage seen in the later stages of severe COVID-19.<sup>63,85,86</sup> In a high-content screen for mucin-1-reducing compounds, a biochemical marker predicting ARDS, fostamatinib reduced mucin-1 *in vitro* and *in vivo*.<sup>87</sup> However, all SYK inhibitors reduce T- and B-cell frequency and activation, potentially impairing an adequate adaptive immune response.<sup>28,33,63,73,88</sup> Therefore, SYK inhibitors are expected to be of therapeutic benefit, primarily in the initial phase of the disease.

### BCR-Abl inhibitors

Prior to injection of viral RNA into the host cytoplasm for replication, all enveloped viruses, including coronaviruses, must fuse with cellular membranes or with endosomes, which is mediated by Abl proteins.<sup>89</sup> Indeed, in the early phases of infection, imatinib prevents viral entry via Abl-mediated cytoskeletal rearrangement, whereas in later infection phases, imatinib and dasatinib inhibit SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) replication through blocking of the Abl2 protein.<sup>89</sup> In addition to its effects on viral replication, BCR-Abl inhibitor's immunomodulatory effects include attenuation of proinflammatory cytokine release (among them IL-1 $\beta$  and TNF- $\alpha$ ) and reduction of macrophage development and M1 polarization, which means that their application could result in a decrease in, or perhaps even prevention of, severe cases of COVID-19.<sup>23,39,90,91</sup> Nevertheless, BCR-Abl inhibitors also cause a decrease in B-cell numbers, antibody production, and Treg viability.<sup>39,67,72</sup> Therefore, application of BCR-Abl inhibitors could be tested at early stages of the disease, but not at later stages, to preserve long-term memory and adequate antibody formation.<sup>39,67,72</sup> The wide variation in the immunomodulatory effects within this class of TKIs must always be considered carefully when choosing a specific inhibitor.

### PI3K/mTOR inhibitors

PI3K/mTOR signaling was reported to be overactivated in MERS-CoV-infected cell lines, and treatment with the nonselective PI3K inhibitor wortmannin and the mTOR inhibitor rapamycin led to inhibited MERS-CoV infection.<sup>92</sup> The PI3K inhibitors described in this review decrease multiple inflammatory cytokines, including IL-1, TNF- $\alpha$ , IL-10, and IFN- $\gamma$ .<sup>43,93</sup> However, idelalisib reduces cytokine production in macrophages, whereas duvelisib polarizes them to an M1 phenotype, leading to a more proinflammatory state.<sup>22,50,55</sup> Idelalisib and umbralisib reduce exhaustion marker expression on CD8<sup>+</sup> T cells, which may assist in preventing lymphocyte dysfunction and depletion.<sup>93</sup> Therefore, PI3K inhibitors could be useful in innate response modulation by inhibiting viral replication, improving early macrophage activation, and ameliorating the T-cell dysfunction seen in later stages. However, the last should be approached cautiously because hyperinflammatory side effects (due to a decrease in Tregs) are relatively common.<sup>94</sup> Because mTOR inhibitors are known to cause interstitial lung disease, possibly caused by increased monocyte infiltration in lung epithelium, their application in this ARDS-prone disease seems counterintuitive.<sup>24</sup> However, multiple trials of rapamycin are underway to assess the possibility that it might decrease cytokine release and T-cell dysfunction (Table 2).



## JAK inhibitors

The key role of JAK-STAT–mediated cytokines, such as IL-6, IL-10, and TNF- $\alpha$ , in the severity of COVID-19 suggests a role for JAK-STAT inhibitors in ameliorating disease severity.<sup>95</sup> However, blocking the JAK-STAT pathway strongly inhibits IFN signaling and decreases T-cell proliferation and response.<sup>45,96</sup> Because IFN signaling is instrumental in initiating the innate immune response and in preventing viral replication, JAK-STAT inhibitors should be avoided during the very early stages of the disease.<sup>97</sup> Because preventing the (IFN-triggered) cytokine storm would be highly desirable, attenuating JAK-STAT signaling could very well improve disease outcome when such symptoms are occurring. Indeed, preliminary data from COVID-19 patients treated with the JAK inhibitor baricitinib in the early phases of their disease demonstrated improvements in inflammatory symptoms and in pulmonary function tests.<sup>95</sup> Ruxolitinib treatment was also proven to reduce severe systemic hyperinflammation in a pilot study, with more extensive phase 2 testing underway.<sup>98</sup> Because JAK inhibitors affect T-cell skewing and function, inhibition of an adequate T-cell response to secondary infections might be expected upon prolonged treatment.<sup>45</sup> The JAK inhibitors baricitinib, ruxolitinib, and tofacitinib are being tested in clinical trials (Table 2).

## FLT3 inhibitors

Although FLT3 signaling seems to have a less distinctive role in cytokine production compared with the other pathways mentioned, possible helpful immunomodulatory effects could be expected upon administration of FLT3 inhibitors to COVID-19 patients. Midostaurin treatment leads to macrophage apoptosis and lowers IL-6, IL-10, and TNF- $\alpha$ .<sup>52,65,99</sup> Quizartinib also lowers IL-6 and TNF- $\alpha$ , suggesting that these TKIs might be useful in attenuating the cytokine storm.<sup>100</sup> However, midostaurin also decreases the proliferation and activation of T and B cells. On the other hand, sorafenib and sunitinib increase IFN- $\gamma$  levels, lower PD-1 and CTLA4 expression on T cells, and enhance T-cell responses (primarily Th1 cells) in general, which could hypothetically strengthen the primary immune response against the virus.<sup>42,53,58,62</sup>

## Concluding remarks

Because most kinases play a role in >1 cell type, and because most inhibitors have promiscuous effects, the use of these drugs will affect immune responses at multiple levels. However, depending on the timing, method, and state of cellular development in which cells are exposed to TKIs, specific skewing could be feasible. Use of

kinase inhibitors to mediate specific immune alterations is becoming more widespread, as seen in the treatment of graft-versus-host disease, rheumatoid arthritis, and other immune-mediated diseases, although the specific way in which these TKIs perturb the pathophysiology is often not completely understood.

The recent widespread adoption of dexamethasone treatment in patients with severe COVID-19, based on the RECOVERY trial, will change the need for some of the immunomodulatory schemes described here.<sup>101</sup> Specific subgroups of COVID-19 patients could very well benefit from immunosuppression through the down-regulation of proinflammatory cytokine production achieved by low doses of corticosteroids.<sup>102</sup> Because corticosteroids could also reduce the initial immune responses needed to induce pathogen recognition and control viral replication, the timing of treatment seems to be of paramount importance.<sup>101,102</sup> Thus, well-timed corticosteroid treatment could potentially be combined with, or followed by, regimens with some of the TKIs mentioned in this review. It could also limit the need for TKIs in the later (phase 3 and 4) stages of immunopathological developments, in COVID-19 and other inflammatory diseases.

Expectations are high for the application of TKIs in the treatment of various diseases that display imbalances in immune functions. Investigating their effects in clinical trials necessitates careful timing of treatment initiation and treatment duration, as well as close immune monitoring using biomarkers of the innate and adaptive immune response. The severity of the current pandemic will no doubt accelerate clinical testing, which can provide the requisite insight, hopefully in the nearby future.

## Authorship

Contribution: C.F.J., E.E., and A.P.K. selected and collected data and wrote the manuscript.

Conflict-of-interest disclosure: A.P.K. receives research funding from Janssen, AbbVie, Roche/Genentech, Astra Zeneca, and Celgene and is a member of advisory boards for Janssen, AbbVie, Roche/Genentech, and Juno. E.E. receives research funding from Janssen, AbbVie, Roche/Genentech, Astra Zeneca, and Celgene. C.F.J. declares no competing financial interests.

Correspondence: Arnon P. Kater, Department of Hematology, D3-221.1, Amsterdam University Medical Center, Location AMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands; e-mail: a.p.kater@amsterdamumc.nl.

## References

- Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang YS. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. *Mol Cancer*. 2018;17(1):36.
- Guidelines N-C-T. Kinase inhibitors: Bruton's tyrosine kinase inhibitors and Janus kinase inhibitors. Available at: <https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/immunomodulators/kinase-inhibitors>. Accessed 17 July 2020.
- Chaplin DD. Overview of the immune response. *J Allergy Clin Immunol*. 2010;125(suppl 2):S3-S23.
- Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nat Immunol*. 2010;11(5):373-384.
- Weber ANR, Bittner Z, Liu X, Dang TM, Radsak MP, Brunner C. Bruton's tyrosine kinase: an emerging key player in innate immunity. *Front Immunol*. 2017;8:1454.
- Baruzzi A, Berton G. The tyrosine kinase Abl is a component of macrophage podosomes and is required for podosome formation and function. *Eur J Immunol*. 2012;42(10):2720-2726.

7. Tong H, Zhao B, Shi H, et al. c-Abl tyrosine kinase plays a critical role in  $\beta$ 2 integrin-dependent neutrophil migration by regulating Vav1 activity. *J Leukoc Biol.* 2013;93(4):611-622.
8. Futosi K, Fodor S, Mócsai A. Neutrophil cell surface receptors and their intracellular signal transduction pathways. *Int Immunopharmacol.* 2013;17(3):638-650.
9. Fiedler K, Sindrilaru A, Terszowski G, et al. Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia. *Blood.* 2011;117(4):1329-1339.
10. Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. *Nat Rev Immunol.* 2010;10(6):387-402.
11. Weichhart T, Säemann MD. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. *Ann Rheum Dis.* 2008;67(suppl 3):iii70-iii74.
12. Tundwal K, Alam R. JAK and Src tyrosine kinase signaling in asthma. *Front Biosci.* 2012;17(7):2107-2121.
13. Bao Y, Zheng J, Han C, et al. Tyrosine kinase Btk is required for NK cell activation [published correction appears in *J Biol Chem.* 2020;295(10):3389]. *J Biol Chem.* 2012;287(28):23769-23778.
14. Gotthardt D, Trifinopoulos J, Sexl V, Putz EM. JAK/STAT cytokine signaling at the crossroad of NK cell development and maturation. *Front Immunol.* 2019;10:2590.
15. Tsapogas P, Mooney CJ, Brown G, Rolink A. The cytokine Flt3-ligand in normal and malignant hematopoiesis. *Int J Mol Sci.* 2017;18(6):1115.
16. Silberman I, Sionov RV, Zuckerman V, et al. T cell survival and function requires the c-Abl tyrosine kinase. *Cell Cycle.* 2008;7(24):3847-3857.
17. Puri KD, Gold MR. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. *Front Immunol.* 2012;3:256.
18. Herman SEM, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. *Blood.* 2011;117(23):6287-6296.
19. Rix U, Hantschel O, Dürnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. *Blood.* 2007;110(12):4055-4063.
20. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. *Arthritis Rheum.* 2011;63(2):337-345.
21. Shi JG, Chen X, McGee RF, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. *J Clin Pharmacol.* 2011;51(12):1644-1654.
22. Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K- $\delta$ , $\gamma$  inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. *Blood.* 2018;131(8):888-898.
23. Hayashi Y, Nakamae H, Katayama T, et al. Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. *Leuk Lymphoma.* 2012;53(6):1084-1089.
24. Washino S, Ando H, Ushijima K, et al. Temsirolimus induces surfactant lipid accumulation and lung inflammation in mice. *Am J Physiol Lung Cell Mol Physiol.* 2014;306(12):L1117-L1128.
25. Prezzo A, Cavaliere FM, Bilotta C, et al. Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment. *Leuk Res.* 2019;87:106233.
26. Papin A, Tessoulin B, Bellanger C, et al. CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages. *Leukemia.* 2019;33(10):2442-2453.
27. Alflen A, Stadler N, Aranda Lopez P, et al. Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses. *Sci Rep.* 2018;8(1):5558.
28. Le Huu D, Kimura H, Date M, et al. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease. *J Dermatol Sci.* 2014;74(3):214-221.
29. Pattison MJ, Mackenzie KF, Arthur JS. Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback. *J Immunol.* 2012;189(6):2784-2792.
30. Pardanani A, Tefferi A, Jamieson C, et al. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. *Blood Cancer J.* 2015;5(8):e335.
31. Natarajan G, Oghumu S, Terrazas C, Varikuti S, Byrd JC, Satoskar AR. A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells. *Oncol Immunology.* 2016;5(6):e1151592.
32. Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. *Blood.* 2013;122(7):1192-1202.
33. Colonna L, Catalano G, Chew C, et al. Therapeutic targeting of Syk in autoimmune diabetes. *J Immunol.* 2010;185(3):1532-1543.
34. Huang YC, Shieh HR, Chen YJ. Midostaurin (PKC412) modulates differentiation and maturation of human myeloid dendritic cells. *Toxicol In Vitro.* 2010;24(6):1705-1710.
35. Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. *Blood.* 2008;111(12):5610-5620.
36. Larmonier N, Janikashvili N, LaCasse CJ, et al. Imatinib mesylate inhibits CD4<sup>+</sup> CD25<sup>+</sup> regulatory T cell activity and enhances active immunotherapy against BCR-ABL<sup>+</sup> tumors. *J Immunol.* 2008;181(10):6955-6963.

37. Appel S, Boehmler AM, Grünebach F, et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. *Blood*. 2004;103(2):538-544.
38. Wolf D, Tilg H, Rumpold H, Gastl G, Wolf AM. The kinase inhibitor imatinib—an immunosuppressive drug? *Curr Cancer Drug Targets*. 2007;7(3):251-258.
39. Marinelli Busilacchi E, Costantini A, Viola N, et al. Immunomodulatory effects of tyrosine kinase inhibitor in vitro and in vivo study. *Biol Blood Marrow Transplant*. 2018;24(2):267-275.
40. Schönberg K, Rudolph J, Vonnahme M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. *Cancer Res*. 2015;75(11):2187-2199.
41. Curran SA, Shyer JA, St Angelo ET, et al. Human dendritic cells mitigate NK-cell dysfunction mediated by nonselective JAK1/2 blockade. *Cancer Immunol Res*. 2017;5(1):52-60.
42. Sprinzl MF, Reisinger F, Puschnik A, et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. *Hepatology*. 2013;57(6):2358-2368.
43. Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase- $\delta$  inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. *Blood*. 2010;116(12):2078-2088.
44. Da Roit F, Engelberts PJ, Taylor RP, et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. *Haematologica*. 2015;100(1):77-86.
45. Hofland T, de Weerd I, Ter Burg H, et al. Dissection of the effects of JAK and BTK inhibitors on the functionality of healthy and malignant lymphocytes. *J Immunol*. 2019;203(8):2100-2109.
46. Pavlasova G, Mraz M. The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy. *Haematologica*. 2020;105(6):1494-1506.
47. Long M, Beckwith K, Do P, et al. Ibrutinib treatment improves T cell number and function in CLL patients. *J Clin Invest*. 2017;127(8):3052-3064.
48. Zou YX, Zhu HY, Li XT, et al. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. *Hematol Oncol*. 2019;37(4):392-400.
49. Greenwell IB, Ip A, Cohen JB. PI3K inhibitors: understanding toxicity mechanisms and management. *Oncology (Williston Park)*. 2017;31(11):821-828.
50. Maharaj K, Powers JJ, Achille A, et al. The dual PI3K $\delta$ /CK1 $\epsilon$  inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. *Blood Adv*. 2020;4(13):3072-3084.
51. Lussana F, Cattaneo M, Rambaldi A, Squizzato A.. Ruxolitinib-associated infections: a systematic review and meta-analysis. *Am J Hematol*. 2018;93(3):339-347.
52. Gutierrez L, Jang M, Zhang T, Akhtari M, Alachkar H. Midostaurin reduces regulatory T cell markers in acute myeloid leukemia. *Sci Rep*. 2018;8(1):17544.
53. Kalathil SG, Lugade AA, Miller A, Iyer R, Thanavala Y. PD-1<sup>+</sup> and Foxp3<sup>+</sup> T cell reduction correlates with survival of HCC patients after sorafenib therapy. *JCI Insight*. 2016;1(11):e86182.
54. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. *Blood*. 2013;122(15):2539-2549.
55. Pleyer C, Wiestner A, Sun C. Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia. *Leuk Lymphoma*. 2018;59(12):2792-2800.
56. Mhibik M, Wiestner A, Sun C. Harnessing the effects of BTKi on T cells for effective immunotherapy against CLL. *Int J Mol Sci*. 2019;21(1):68.
57. Hofland T, Eldering E, Kater AP, Tonino SH. Engaging cytotoxic T and NK cells for immunotherapy in chronic lymphocytic leukemia. *Int J Mol Sci*. 2019;20(17):4315.
58. Heine A, Held SA, Bringmann A, Holderried TA, Brossart P. Immunomodulatory effects of anti-angiogenic drugs. *Leukemia*. 2011;25(6):899-905.
59. Iyer RV, Maguire O, Kim M, et al. Dose-dependent sorafenib-induced immunosuppression is associated with aberrant NFAT activation and expression of PD-1 in T cells. *Cancers (Basel)*. 2019;11(5):681.
60. Beziaud L, Mansi L, Ravel P, et al. Rapalogs efficacy relies on the modulation of antitumor T-cell immunity. *Cancer Res*. 2016;76(14):4100-4112.
61. Wolleschak D, Mack TS, Perner F, et al. Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. *Haematologica*. 2014;99(6):e90-e93.
62. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. *Clin Cancer Res*. 2008;14(20):6674-6682.
63. Colado A, Almejún MB, Podaza E, et al. The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients. *Cancer Immunol Immunother*. 2017;66(4):461-473.
64. McLornan DP, Khan AA, Harrison CN. Immunological consequences of JAK inhibition: friend or foe? *Curr Hematol Malign Rep*. 2015;10(4):370-379.
65. Si MS, Reitz BA, Borie DC. Effects of the kinase inhibitor CGP41251 (PKC 412) on lymphocyte activation and TNF-alpha production. *Int Immunopharmacol*. 2005;5(7-8):1141-1149.
66. Appel S, Balabanov S, Brümendorf TH, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. *Stem Cells*. 2005;23(8):1082-1088.
67. Rajala HLM, Missiry ME, Ruusila A, et al. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. *J Cancer Res Clin Oncol*. 2017;143(8):1543-1554.

68. Burger JA, Sivina M, Jain N, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. *Blood*. 2019;133(10):1011-1019.
69. Jaglowski SM, Blazar BR. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. *Blood Adv*. 2018;2(15):2012-2019.
70. Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib [published correction appears in *Blood*. 2016;128(7):1020]. *Blood*. 2015;126(19):2213-2219.
71. Sun C, Gao J, Couzens L, et al. Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib. *JAMA Oncol*. 2016;2(12):1656-1657.
72. Steegmann JL, Moreno G, Aláez C, et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. *Haematologica*. 2003;88(7):762-768.
73. Coffey G, Betz A, DeGuzman F, et al. The novel kinase inhibitor PRT062070 (cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer. *J Pharmacol Exp Ther*. 2014;351(3):538-548.
74. Majumder MM, Leppä AM, Hellesøy M, et al. Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. *Haematologica*. 2020;105(6):1527-1538.
75. Cunha LL, Perazzo SF, Azzi J, Cravedi P, Riella LV. Remodeling of the immune response with aging: immunosenescence and its potential impact on COVID-19 immune response. *Front Immunol*. 2020;11:1748.
76. Yang L, Liu S, Liu J, et al. COVID-19: immunopathogenesis and Immunotherapeutics. *Signal Transduct Target Ther*. 2020;5(1):128.
77. Chang BY, Huang MM, Francesco M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. *Arthritis Res Ther*. 2011;13(4):R115.
78. Rip J, Van Der Ploeg EK, Hendriks RW, Corneth OBJ. The role of Bruton's tyrosine kinase in immune cell signaling and systemic autoimmunity. *Crit Rev Immunol*. 2018;38(1):17-62.
79. Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. *Blood*. 2020;135(21):1912-1915.
80. Molina-Cerrillo J, Alonso-Gordoa T, Gajate P, Grande E. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors. *Cancer Treat Rev*. 2017;58:41-50.
81. McGee MC, August A, Huang W. BTK/ITK dual inhibitors: modulating immunopathology and lymphopenia for COVID-19 therapy [published online ahead of print 8 July 2020]. *J Leukoc Biol*. doi:10.1002/JLB.5COVR0620-306R.
82. Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. *Sci Immunol*. 2020;5(48):eabd0110.
83. AstraZeneca. Update on CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19. Available at: <https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-calavi-phase-ii-trials-for-calquence-in-patients-hospitalised-with-respiratory-symptoms-of-covid-19.html>. Accessed 9 December 2020.
84. McAdoo SP, Reynolds J, Bhargal G, et al. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN. *J Am Soc Nephrol*. 2014;25(10):2291-2302.
85. Yoshimoto T, Hayashi T, Kondo T, Kittaka M, Reichenberger EJ, Ueki Y. Second-generation SYK inhibitor entospletinib ameliorates fully established inflammation and bone destruction in the cherubism mouse model. *J Bone Miner Res*. 2018;33(8):1513-1519.
86. Poe JC, Jia W, Di Paolo JA, et al. SYK inhibitor entospletinib prevents ocular and skin GVHD in mice. *JCI Insight*. 2018;3(19):e122430.
87. Alimova M, Sidhom EH, Satyam A, et al. A high content screen for mucin-1-reducing compounds identifies fostamatinib as a candidate for rapid repurposing for acute lung injury during the COVID-19 pandemic. *bioRxiv*. Preprint 20 Jun 2020. doi:10.1101/2020.06.30.180380
88. Zhu Y, Herlaar E, Masuda ES, et al. Immunotoxicity assessment for the novel spleen tyrosine kinase inhibitor R406. *Toxicol Appl Pharmacol*. 2007;221(3):268-277.
89. Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. *J Gen Virol*. 2018;99(5):619-630.
90. Dewar AL, Domaschitz RM, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. *Leukemia*. 2003;17(9):1713-1721.
91. Baruzzi A, Iacobucci I, Soverini S, Lowell CA, Martinelli G, Berton G. c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration. *FEBS Lett*. 2010;584(1):15-21.
92. Kindrachuk J, Ork B, Hart BJ, et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. *Antimicrob Agents Chemother*. 2015;59(2):1088-1099.
93. Dwyer CJ, Arhontoulis DC, Rangel Rivera GO, et al. Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8<sup>+</sup> T cells. *Eur J Immunol*. 2020;50(9):1386-1399.
94. Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. *Blood*. 2016;128(2):195-203.
95. Spinelli FR, Conti F, Gadina M. Hijacking SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19. *Sci Immunol*. 2020;5(47):
96. Massalska M, Maslinski W, Ciechomska M. Small molecule inhibitors in the treatment of rheumatoid arthritis and beyond: latest updates and potential strategy for fighting COVID-19. *Cells*. 2020;9(8):1876.

97. Walz L, Cohen AJ, Rebaza AP, et al. Janus kinase-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. *medRxiv*. Preprint 20 Aug 2020.
98. La Rosée F, Bremer HC, Gehrke I, et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. *Leukemia*. 2020;34(7):1805-1815.
99. Miyatake K, Inoue H, Hashimoto K, et al. PKC412 (CGP41251) modulates the proliferation and lipopolysaccharide-induced inflammatory responses of RAW 264.7 macrophages. *Biochem Biophys Res Commun*. 2007;360(1):115-121.
100. Wang R, Chen T, Wang C, et al. Flt3 inhibition alleviates chronic kidney disease by suppressing CD103+ dendritic cell-mediated T cell activation. *Nephrol Dial Transplant*. 2019;34(11):1853-1863.
101. Horby P, Lim WS, Emberson JR, et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19—preliminary report [published online ahead of print 17 July 2020]. *N Engl J Med*. doi:10.1056/NEJMoa2021436.
102. Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmacologic-immunomodulatory therapy in COVID-19. *Drugs*. 2020;80(13):1267-1292.
103. Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies [published correction appears in *Mol Cancer*. 2019;18(1):79]. *Mol Cancer*. 2018;17(1):57.
104. Pula B, Golos A, Górniak P, Jamrozik K. Overcoming ibrutinib resistance in chronic lymphocytic leukemia. *Cancers (Basel)*. 2019;11(12):1834.
105. Syed YY. Zanubrutinib: first approval. *Drugs*. 2020;80(1):91-97.
106. Liu D, Mamorska-Dyga A. Syk inhibitors in clinical development for hematological malignancies. *J Hematol Oncol*. 2017;10(1):145.
107. Bussel JB, Arnold DM, Boxer MA, et al. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. *Am J Hematol*. 2019;94(5):546-553.
108. Rolf MG, Curwen JO, Veldman-Jones M, et al. In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. *Pharmacol Res Perspect*. 2015;3(5):e00175.
109. Salesse S, Verfaillie CM. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. *Oncogene*. 2002;21(56):8547-8559.
110. Sacha T, Saglio G. Nilotinib in the treatment of chronic myeloid leukemia. *Future Oncol*. 2019;15(9):953-965.
111. Tan FH, Putoczki TL, Stylli SS, Luwor RB. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. *OncoTargets Ther*. 2019;12:635-645.
112. Kwak JY, Kim SH, Oh SJ, et al. Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia. *Clin Cancer Res*. 2017;23(23):7180-7188.
113. Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. *Annu Rev Med*. 2016;67(1):11-28.
114. Sapon-Cousineau V, Sapon-Cousineau S, Assouline S. PI3K inhibitors and their role as novel agents for targeted therapy in lymphoma. *Curr Treat Options Oncol*. 2020;21(6):51.
115. Patel K, Danilov AV, Pagel JM. Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma. *Blood*. 2019;134(19):1573-1577.
116. Burris HA, Flinn IW, Patel MR, et al. Umbralisib, a novel PI3K $\delta$  and casein kinase-1 $\epsilon$  inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. *Lancet Oncol*. 2018;19(4):486-496.
117. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. *Front Oncol*. 2014;4:64.
118. Zeiser R, von Bubnoff N, Butler J, et al; REACH2 Trial Group. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. *N Engl J Med*. 2020;382(19):1800-1810.
119. Harrison CN, Schaap N, Mesa RA. Management of myelofibrosis after ruxolitinib failure. *Ann Hematol*. 2020;99(6):1177-1191.
120. Ragheb M, Harrison CN, McLornan DP. Current and future role of fedratinib in the treatment of myelofibrosis. *Future Oncol*. 2020;16(6):175-186.
121. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. *Leukemia*. 2009;23(8):1441-1445.
122. Jain T, Mesa R. The development, safety and efficacy of pacritinib for the treatment of myelofibrosis. *Expert Rev Anticancer Ther*. 2016;16(11):1101-1108.
123. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. *Leukemia*. 2019;33(2):299-312.
124. Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. *Mol Cancer Ther*. 2017;16(6):991-1001.
125. Roskoski R. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias. *Pharmacol Res*. 2020;155:104725.